8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 11, 2022

ALX ONCOLOGY HOLDINGS INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware	001-39386	85-0642577
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
323 Allerton Avenue, South San Francisco, California		94080
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 466-7125

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	ALXO	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.

Effective as of April 11, 2022, the Board of Directors of ALX Oncology Holdings Inc. (the “Company”) appointed Dr. Itziar Canamasas to its Board of Directors and increased the size of its Board of Directors from six to seven directors in connection with her appointment. The appointment was made based upon the recommendation of the Corporate Governance and Nominating Committee of the Company’s Board of Directors. Dr. Canamasas has been designated as a Class II director for a term expiring at the Company’s 2022 Annual Meeting of Stockholders.

Dr. Canamasas currently serves as the Head of Oncology Europe, Middle East and Africa at Bayer AG. During her 20 plus years at Bayer, Dr. Canamasas has held various oncology leadership positions with expertise focused on global commercialization, strategic life-cycle development and corporate strategy, including roles as Vice President of Global Marketing Oncology and Managing Director of Bayer Limited. Dr. Canamasas is also the Organizational Development Director for the Ambassador Program at the Healthcare Businesswomen’s Association (HBA). Dr. Canamasas holds an M.S. in Biology with distinction from the Universitat de Barcelona and a Ph.D. in Cancer Genetics from the University of Mainz.
 

In accordance with the Company’s outside director compensation policy (the “policy”) and in connection with her appointment on April 11, 2022, Dr. Canamasas was automatically granted an initial award of stock options to purchase 24,009 shares of the Company’s common stock (the “Initial Award”). The Initial Award is scheduled to vest in equal installments as to one thirty-sixth of the shares subject to the Initial Award on a monthly basis following the Initial Award’s grant date, on the same day of the month as the grant date, subject to continued services to the Company through the applicable vesting date. Dr. Canamasas shall also be entitled to annual cash compensation and equity awards under the terms of the policy. In addition, the Company entered into an indemnification agreement with Dr. Canamasas in the same form as the Company’s other directors.

There are no arrangements or understandings between Dr. Canamasas and any other person pursuant to which she was selected to serve on the Company’s Board of Directors. There are no transactions in which the Company or any of its subsidiaries is a party and in which Dr. Canamasas has a material interest subject to disclosure under Item 404(a) of Regulation S-K.

On April 12, 2022, the Company, issued a press release announcing the appointment of Dr. Canamasas to its Board of Directors effective as of April 11, 2022. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Exhibit Number	Description
99.1	Press Release dated April 12, 2022
104	Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ALX ONCOLOGY HOLDINGS INC.
Date: April 12, 2022	By:	/s/ Peter Garcia
		Peter Garcia
		Chief Financial Officer

EX-99.1

  Exhibit 99.1

ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors

SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway,today announced the appointment of Itziar Canamasas, Ph.D., to its Board of Directors (the “Board”) effective April 11, 2022. With more than 20 years of biopharmaceutical industry experience, Dr. Canamasas brings expertise in driving business growth and operational excellence.

“We are excited to welcome Dr. Canamasas to our Board during an important time in ALX Oncology’s continued evolution,” said Corey Goodman, Ph.D., Executive Chairman of ALX Oncology. “Dr. Canamasas provides a proven track record of successful oncology product launches and transformational strategic expertise to ALX Oncology that will be instrumental in 2022 and beyond as we execute on helping patients fight cancer.”

“I am excited to join the Board at this pivotal junction in ALX Oncology’s growth trajectory. I look forward to working closely with the management team and fellow Board members to execute on advancing evorpacept to reach its full potential as a therapy for patients with hematological and solid tumors,” said Dr. Canamasas.

Dr. Canamasas currently serves as the Head of Oncology Europe, Middle East and Africa at Bayer AG. During her 20 plus years at Bayer, Dr. Canamasas has held various oncology leadership positions with expertise focused on global commercialization, strategic life-cycle development and corporate strategy, including roles as Vice President of Global Marketing Oncology and Managing Director of Bayer Limited. Dr. Canamasas is also the Organizational Development Director for the Ambassador Program at the Healthcare Businesswomen’s Association (HBA). Dr. Canamasas holds an M.S. in Biology with distinction from the Universitat de Barcelona and a Ph.D. in Cancer Genetics from the University of Mainz.

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of evorpacept for the treatment of multiple solid tumor indications and hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndromes.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans and objects of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology’s actual

results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology’s filings with the Securities and Exchange Commission (“SEC”), including ALX Oncology’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:

Peter Garcia

Chief Financial Officer, ALX Oncology

(650) 466-7125 Ext. 113

peter@alxoncology.com

Argot Partners

(212)-600-1902

alxoncology@argotpartners.com

Media Contact:

Karen Sharma

MacDougall

(781) 235-3060

alx@macbiocom.com

XML

Document and Entity Information	Apr. 11, 2022
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Apr. 11, 2022
Entity Registrant Name	ALX ONCOLOGY HOLDINGS INC.
Entity Central Index Key	0001810182
Entity Emerging Growth Company	false
Entity File Number	001-39386
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-0642577
Entity Address, Address Line One	323 Allerton Avenue
Entity Address, City or Town	South San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94080
City Area Code	650
Local Phone Number	466-7125
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Security 12b Title	Common Stock, $0.001 par value per share
Trading Symbol	ALXO
Security Exchange Name	NASDAQ